• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Infinity Pharmaceuticals, Inc.

    Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN)
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI MEIP
    Infinity Pharmaceuticals Announces Two Upcoming Presentations on PI3K-γ and Eganelisib by Dr. Judith Varner at the 2023 Annual Meeting of the American Association of Cancer Research
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Reports Full Year 2022 Financial Results
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals to Participate in Piper Sandler 34th Annual Healthcare Conference
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Provides MARIO-3 Update in Patients with Front Line Metastatic Triple Negative Breast Cancer Suggesting Potential Long-Term Patient Benefit of Eganelisib
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Announces the Date of Its Second Quarter 2022 Financial Results Conference Call and Webcast
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Announces the Date of Its First Quarter 2022 Financial Results Conference Call and Webcast
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals to Be Featured in a Fireside Chat as Part of B. Riley’s 2022 Virtual Oncology Conference
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity to Present at 40th Annual J.P. Morgan Healthcare Conference
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Added to the NASDAQ Biotechnology Index
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals to be Featured in B. Riley Fireside Chat
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Encouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals to Host an Investor Event on Updated MARIO-3 Data Presented at the 2021 San Antonio Breast Cancer Symposium
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Infinity Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
    From Infinity Pharmaceuticals, Inc.
    Via Business Wire
    Tickers INFI
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.